Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inspecs GroupLSE:SPEC -1.03%50 EV-to-EBITDA is 10.25 as of Jul. 23, 2026, which is 80% above its 10-year median of 5.70. GuruFocus rates LSE:SPEC with a GF Score™ of 50/100 and a GF Value™ of £0.58 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Inspecs Group ranks better than 66.08% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Inspecs Group's enterprise value is £148.6 Mil.
Inspecs Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £14.5 Mil. Therefore, Inspecs Group's EV-to-EBITDA for today is 10.25.
The historical rank and industry rank for Inspecs Group's EV-to-EBITDA or its related term are showing as below:
LSE:SPEC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.75 Med: 5.7 Max: 77.96
Current: 10.25
During the past 10 years, the highest EV-to-EBITDA of Inspecs Group was 77.96. The lowest was -68.75. And the median was 5.70.
LSE:SPEC's EV-to-EBITDA is ranked better than 66.08% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.08
vs LSE:SPEC: 10.25
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Inspecs Group (LSE:SPEC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Inspecs Group's PE Ratio (TTM) for today is calculated as:
Inspecs Group's share price for today is £0.96.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Inspecs Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.094.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Inspecs Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:SPEC vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Inspecs Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inspecs Group EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Inspecs Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Inspecs Group's EV-to-EBITDA falls into.
Inspecs Group's current Enterprise Value is £148.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Inspecs Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was £14.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inspecs Group (LSE:SPEC) has a EV-to-EBITDA of 10.25 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inspecs Group. This is 80% above median its historical median of 5.70. According to the industry distribution chart, Inspecs Group ranks #173 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 33.9%.
Is Inspecs Group's EV-to-EBITDA too high?
Inspecs Group's current EV-to-EBITDA of 10.25 is 80% above median its 10-year median of 5.70. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.08. Inspecs Group's value of 10.25 is 27.2% below this industry median. Based on the distribution chart, Inspecs Group ranks #173 out of 510 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Inspecs Group has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inspecs Group's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Inspecs Group ranks #173 out of 510 companies for EV-to-EBITDA. This puts Inspecs Group in the upper half of its industry. The industry median EV-to-EBITDA is 14.08. Inspecs Group's value of 10.25 is 27.2% below this benchmark. While the company's 10-year median is 5.70 vs. the industry median of 14.08, Inspecs Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.08, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inspecs Group's current EV-to-EBITDA of 10.25 is 27.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Inspecs Group. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inspecs Group's current EV-to-EBITDA is 10.25, which is 80% above median its own 10-year median of 5.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspecs Group stock overvalued right now?
Based on GuruFocus' analysis, Inspecs Group (LSE:SPEC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.58, compared to a current price of £0.96 — trading 65.5% above its estimated fair value. The current EV-to-EBITDA is 10.25, which is 80% above median its 10-year median of 5.70 and 27.2% below the Medical Devices & Instruments industry median of 14.08. Inspecs Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Inspecs Group (LSE:SPEC), the current EV-to-EBITDA is 10.25 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inspecs Group (LSE:SPEC) Overvalued in 2026?
Based on GuruFocus' analysis, Inspecs Group stock appears to be overvalued.
The current stock price of £0.96 is trading 65.5% above its estimated GF Value™ of £0.58.
GuruFocus considers Inspecs Group to be Significantly Overvalued.
Key valuation signals for LSE:SPEC:
EV-to-EBITDA: 10.25 (80% above median its 10-year median of 5.70)
GF Value™: £0.58 vs. price of £0.96 (65.5% above fair value)
Industry Position: 27.2% below the Medical Devices & Instruments median (#173 of 510)
No single metric tells the full story. See the LSE:SPEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inspecs Group PLC is a designer and manufacturer of eyewear frames and accessories. The customers of the company include optical and Non-optical retailers, distributors, and independent opticians. The company operations are spread across the United Kingdom, Europe (excluding the UK), South America, North America, Asia, Africa, and Australia. Its eyewear brands include Superdry, Titanflex, O'Neill, Brendel, Humphreys, Marc O'Polo, and among others. The reporting segments of the company are Frames and Optics product distribution which derives maximum revenue, and Manufacturing includes OEM and manufacturing distribution segment.
50GF Score
Get the complete analysis for LSE:SPEC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SPEC has been successfully added to your 
